| Symbol | GYRE |
|---|---|
| Name | GYRE THERAPEUTICS, INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Address | 12770 HIGH BLUFF DRIVE,SUITE 150, SAN DIEGO, California, 92130, United States |
| Telephone | +1 858 567-7770 |
| Fax | — |
| — | |
| Website | https://www.gyretx.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001124105 |
| Description | Gyre Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is engaged in the research, development, manufacturing, and commercialization of drugs for organ fibrosis. It is primarily focused on the development and commercialization of F351 (Hydronidone) for the treatment of Nonalcoholic Steatohepatitis Treatment (NASH)-associated fibrosis. The Company is also advancing a diverse pipeline in the China through its indirect controlling interest in Gyre Pharmaceuticals, including ETUARY therapeutic expansions, F573, F528, and F230. The Company operates through two segments: Gyre Pharmaceuticals, and Gyre after the Contributions. The Gyre Pharmaceuticals has one major commercial drug product, ETUARY, and several product candidates in pre-clinical and clinical development. Gyre is a biopharmaceutical company focused on the development and commercialization of F351 for the treatment of non-alcoholic steatohepatitis-associated liver fibrosis in the United States. Additional info from NASDAQ: |
(10% Negative) GYRE THERAPEUTICS, INC. (GYRE) Reports Q3 2026 Financial Results
Read moreGyre Therapeutics Reports Second Quarter 2026 and Year-to-Date Financial Results and Provides Business Update
Read more(99% Neutral) GYRE THERAPEUTICS, INC. (GYRE) Announces Enrollment Update for operations Due to Patient Enrollment Issues, Manufacturing Considerations
Read moreNew Form 8-K/A - GYRE THERAPEUTICS, INC. <b>Filed:</b> 2026-07-15 <b>AccNo:</b> 0001140361-26-028564 <b>Size:</b> 2 MB <br />Item 2.02: Results of Operations and Financial Condition <br />Item 9.01: Financial Statements and Exhibits
Read moreCarmichael Gordon 🟢 acquired 40.0K shares (1 derivative) of GYRE THERAPEUTICS, INC. (GYRE) at $5.95 Transaction Date: Jun 10, 2026 | Filing ID: 027008
Read moreEpstein David M. 🟢 acquired 40.0K shares (1 derivative) of GYRE THERAPEUTICS, INC. (GYRE) at $5.95 Transaction Date: Jun 10, 2026 | Filing ID: 027007
Read moreWeng Dan 🟢 acquired 40.0K shares (1 derivative) of GYRE THERAPEUTICS, INC. (GYRE) at $5.95 Transaction Date: Jun 10, 2026 | Filing ID: 027006
Read moreParry Renate 🟢 acquired 40.0K shares (1 derivative) of GYRE THERAPEUTICS, INC. (GYRE) at $5.95 Transaction Date: Jun 10, 2026 | Filing ID: 027005
Read moreZhang Ping 🟢 acquired 40.0K shares (1 derivative) of GYRE THERAPEUTICS, INC. (GYRE) at $5.95 Transaction Date: Jun 10, 2026 | Filing ID: 027004
Read more